Hims & Hers Health (HIMS) News Today

Hims & Hers Health, Inc. (NYSE: HIMS) shares are under pressure from a wave of securities lawsuits and insider selling, though strategic initiatives offer offsetting upside. Key developments driving today’s trading:

• Positive Sentiment: Hims & Hers shares spiked after the company confirmed it remains open to collaborate with Novo Nordisk despite the Wegovy partnership ending. HIMS Jumps 8.6% as Firm Still Open to Work With Novo
• Positive Sentiment: The company will expand into Canada by offering generic semaglutide once Novo’s patents expire, broadening its addressable market. Hims & Hers Health, Inc. Announces Expansion To Canada
• Positive Sentiment: A Motley Fool feature highlights Hims & Hers positioning to capitalize on Novo Nordisk’s missteps in the GLP-1 weight-loss segment, underscoring growth potential. Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder
• Neutral Sentiment: Seeking Alpha argues that Hims & Hers’ management is its greatest asset, driving innovation and expansion, though highlighting risks from stock-based compensation and regulatory scrutiny. Why Hims & Hers Management Might Be Its Most Valuable Asset
• Neutral Sentiment: Bloomberg profiles Hims & Hers’ success in producing “knockoff” GLP-1 weight-loss drugs, illustrating operational strength amid intensifying competition. How Hims Became the King of Knockoff Weight-Loss Drugs
• Neutral Sentiment: 247WallStreet lists HIMS among “ridiculously discounted growth stocks,” noting valuation swings but without new company-specific catalysts. 3 Ridiculously Discounted Growth Stocks to Buy Now
• Negative Sentiment: Reuters reports multiple lawsuits have been filed against Hims & Hers following Novo Nordisk’s exit from their Wegovy partnership, increasing legal overhang. Hims & Hers hit with investor lawsuits after Novo ends Wegovy partnership
• Negative Sentiment: Insider Soleil Boughton sold 2,572 HIMS shares at an average price of $47.82, reducing her stake by 1.6%, a signal that insiders may be taking profits. Insider Selling: HIMS Insider Sells 2,572 Shares
• Negative Sentiment: Over a dozen law firms—including Kessler Topaz, Bragar Eagel & Squire, Rosen, Wolf Haldenstein, Berger Montague, Gross, BFA, Glancy Prongay & Murray, DJS, Levi & Korsinsky, Schall, and Kahn Swick & Foti—have issued securities-fraud and class action alerts, warning investors to file by August 25. Kessler Topaz Meltzer & Check, LLP Reminds Hims & Hers Health Investors of Important Deadline...